Oncotelic Therapeutics reports publication on Deciparticle technology supporting Sapu003 development
OTLC•Preclinical results
Preclinical results showed broad systemic distribution with reduced gastrointestinal exposure versus oral everolimus, with no treatment-related gastric pathology in repeat-dose studies.
Publication supports Sapu003 program
Oncotelic Therapeutics reports a peer-reviewed Biomedicines publication validating Deciparticle technology supporting Sapu003, its intravenous everolimus program.
The study package covers ADME, pharmacokinetics, tissue distribution, GLP toxicology and cGMP manufacturing, and supports the ongoing Phase 1 trial in advanced solid tumors.
